ARTICLE | Product Development
Placebo-adjusted weight loss falls short of 25%+ expectations, doesn’t differentiate from Lilly’s Zepbound
By Stephen Hansen, Director of Biopharma Intelligence
December 20, 2024 12:24 PM UTC
Updated on Dec 21, 2024 at 1:04 AM UTC
Novo Nordisk received a lump of coal in its stocking this season. It arrived in the form of Phase III data for its most important weight loss candidate, CagriSema, falling short of expectations — leading investors to cut as much as $150 billion in valuation from the Danish pharma.
Novo Nordisk A/S (CSE:NOVO-B; NYSE:NVO) said Friday that CagriSema led to weight loss of 22.7% after 68 weeks vs. 2.3% for placebo in the Phase III REDEFINE 1 trial, showing statistical significance and meeting its primary endpoint. But the results were short of investor expectations of at least 25% weight loss for the product, which combines amylin agonist cagrilintide and GLP-1R agonist semaglutide…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654546/novo-s-market-cap-slims-down-on-cagrisema-obesity-data